Dirk Heider

Dirk Heider

Auto-generated profile, based on publicly available information

Dirk Heider

Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2016 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
JBJens-Oliver Bock
Jens-Oliver Bock
HKHans-Helmut König
Hans-Helmut König
HBHermann Brenner
Hermann Brenner
WHWalter E. Haefeli
Walter E. Haefeli
RQRenate Quinzler
Renate Quinzler
DHDirk Heider
Dirk Heider
The concept of frailty is rapidly gaining attention as an independent syndrome with high prevalence in older adults. Thereby, frailty is often related to certain adverse outcomes like mortality or disability. Another adverse outcome discussed is increased health care utilization. However, only few studies examined the impact of frailty on health care utilization and corresponding costs. The aim of this study was therefore to investigate comprehensively the relationship between frailty, health care utilization and costs. Cross sectional data from 2598 older participants (57–84 years) recruited in the Saarland, Germany, between 2008 and 2010 was used. Participants passed geriatric assessments that included Fried’s five frailty criteria: weakness, slowness, exhaustion, unintentional weight loss, and physical inactivity. Health care utilization was recorded in the sectors of inpatient treatment, outpatient treatment, pharmaceuticals, and nursing care. Prevalence of frailty (≥3 symptoms) was 8.0 %. Mean total 3-month costs of frail participants were €3659 (4 or 5 symptoms) and €1616 (3 symptoms) as compared to €642 of nonfrail participants (no symptom). Controlling for comorbidity and general socio-demographic characteristics in multiple regression models, the difference in total costs between frail and non-frail participants still amounted to €1917; p < .05 (4 or 5 symptoms) and €680; p < .05 (3 symptoms). Among the 5 symptoms of frailty, weight loss and exhaustion were significantly associated with total costs after controlling for comorbidity. The study provides evidence that frailty is associated with increased health care costs. The analyses furthermore indicate that frailty is an important factor for health care costs independent from pure age and comorbidity. Costs were rather attributable to frailty (and comorbidity) than to age. This stresses that the overlapping concepts of multimorbidity and frailty are both necessary to explain health care use and corresponding costs among older adults.

14 February 2014 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
DHDirk Heider
Dirk Heider
HMHerbert Matschinger
Herbert Matschinger
HMHeiko Müller
Heiko Müller
KSKai-Uwe Saum
Kai-Uwe Saum
RQRenate Quinzler
Renate Quinzler
HKHans-Helmut König
Hans-Helmut König
To analyze the association of health care costs with predisposing, enabling, and need factors, as defined by Andersen’s behavioral model of health care utilization, in the German elderly population.

21 February 2017 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
DHDirk Heider
Dirk Heider
HMHerbert Matschinger
Herbert Matschinger
AMAndreas D. Meid
Andreas D. Meid
RQRenate Quinzler
Renate Quinzler
JAJürgen-Bernhard Adler
Jürgen-Bernhard Adler
HKHans-Helmut König
Hans-Helmut König

31 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDirk Heider
Dirk Heider
HMHerbert Matschinger
Herbert Matschinger
AMAndreas D Meid
Andreas D Meid
RQRenate Quinzler
Renate Quinzler
JAJürgen-Bernhard Adler
Jürgen-Bernhard Adler
HKHans-Helmut König
Hans-Helmut König
In the growing population of the elderly, drug-related problems are considered an important health care safety issue. One aspect of this is the prescription of potentially inappropriate medication (PIM) which is considered to increase health care costs. Using data from the Health Economics of Potentially Inappropriate Medication (HEPIME) study, we aimed to analyze how the number of prescribed substances moderates the association of PIM use as defined by the German PRISCUS list and health care costs applying a longitudinal perspective. An initial number of 6,849,622 insurants aged 65+ of a large German health insurance company were included in a retrospective matched cohort study. Based on longitudinal claims data from the four separate quarters of a 12-month pre-period, 3,860,842 individuals with no exposure to PIM in 2011 were matched to 508,212 exposed individuals. Exposure effects of PIM use on health care costs and the number of prescribed substances were measured based on longitudinal claims data from the four separate quarters of the 12-month post-period. After successful balancing for the development of numerous matching variables during the four quarters of the pre-period, exposed individuals consumed 2.1 additional prescribed substances and had higher total health care costs of 1,237 € when compared to non-exposed individuals in the 1st quarter of the post-period. Controlling for the number of prescribed substances, the difference in total health care costs between both study groups was 401 €. The average effect of one additionally prescribed substance (other than PIM) on total health care costs was increased by an amount of 137 € for those being exposed to a PIM. In quarters 2–4 of the post-period, the differences between both study groups tended to decrease sequentially. PIM use has an increasing effect on the development of health care costs. This cost-increasing effect of PIM use is moderated by the number of prescribed substances.


16 September 2016 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
AMAndreas D. Meid
Andreas D. Meid
DHDirk Heider
Dirk Heider
JAJürgen-Bernhard Adler
Jürgen-Bernhard Adler
RQRenate Quinzler
Renate Quinzler
HBHerrmann Brenner
Herrmann Brenner
WHWalter E. Haefeli
Walter E. Haefeli